Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04817254|
Recruitment Status : Recruiting
First Posted : March 26, 2021
Last Update Posted : February 1, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Glioblastoma (GBM) is a type of malignant glioma. These cancers are nearly always fatal. People who develop these cancers get aggressive treatments. But the tumors almost always recur. Researchers want to study people with newly diagnosed disease to learn more.
To study people with newly diagnosed GBM or gliosarcoma to look at the changes in immune cells in the blood of those who take ipilimumab and nivolumab, along with temozolomide.
Adults ages 18 and older with newly diagnosed GBM or gliosarcoma, who have had surgical removal of their tumor and have completed standard initial chemotherapy and radiation therapy.
Participants will be screened with the following:
Medical record review
Tests to assess their nervous system and their ability to do typical activities
Tumor assessment. For this, they will have magnetic resonance imaging (MRI). They may get a contrast dye through an intravenous (IV) catheter. The MRI scanner makes noise. They will get earplugs.
Electrocardiogram. It measures heart rate and rhythm. They will lie still. Sticky pads will be placed on their chest, arms, and legs.
Screening tests will be repeated during the study.
Treatment will be given in cycles. Each cycle lasts 4 weeks. Participants will get nivolumab and ipilimumab via IV. They will take temozolomide by mouth. They will keep a pill diary.
Participants will fill out surveys about their symptoms.
Participants will have follow-up visits about 60 days and 100 days after treatment ends. Then they will be contacted every 6 months for the rest of their life.
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma Gliosarcoma Malignant Glioma||Drug: TMZ Drug: ipilimumab 3mg/kg Drug: Nivolumab Drug: ipilimumab 1mg/kg||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma|
|Actual Study Start Date :||December 8, 2021|
|Estimated Primary Completion Date :||November 30, 2025|
|Estimated Study Completion Date :||December 31, 2026|
Experimental: Arm 1
Nivolumab + Ipilimumab 1mg/kg + TMZ
150 mg/m2 on days 1-5 of cycles 1-6
1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16
Drug: ipilimumab 1mg/kg
1 mg/kg q 4 weeks for cycles 1-4
Experimental: Arm 2
Nivolumab + Ipilimumab 3mg/kg + TMZ
150 mg/m2 on days 1-5 of cycles 1-6
Drug: ipilimumab 3mg/kg
3 mg/kg q 4 weeks for cycles 1-4
1 mg/kg IV q2weeks for cycles 1-4, then 480 mg q 4 weeks for cycles 5-16
- Determine if the outcomes, as measured by overall survival, is improved in patients with newly diagnosed glioblastoma when treatment with immune checkpoint inhibitors result in an immune response in peripheral blood T lymphocytes. [ Time Frame: death ]Correlation between the Median amount of time subject survives after therapy and quantitative analysis of peripheral blood T lymphocytes.
- Determine if the T cell response measured by the ex vivo tosylactivated bead assay correlates with subsequent systemic response to treatment with immune checkpoint inhibitors. [ Time Frame: Baseline, Day 1 of each Cycle and 60 day and 100 day post treatment ]Correlation between T cell response to immune checkpoint inhibitors and survival
- Determine if T cell response to immune checkpoint inhibitors measuring the change in the pre-treatment and post-treatment blood correlates with progression-free survival [ Time Frame: disease progression ]Measurement of pretreatment and posttreatment blood correlates and its correlation T cell response to checkpoint inhibitors.
- Determine if in vitro peripheral blood T cell response to a stimulation paradigm including nivolumab and ipilimumab correlates with progression-free survival, evaluating 2 different dosing regimens of the ICIs. [ Time Frame: disease progression ]Correlation between T cell response with varying dose regimen of immune checkpoint inhibitors and disease progression
- Determine if in vitro peripheral blood T cell response to a stimulation paradigm including nivolumab and ipilimumab correlates with overall survival, evaluating 2 different dosing regimens of the ICIs. [ Time Frame: death ]Correlation between T cell response with varying dose regimen of immune checkpoint inhibitors and death
- Evaluate changes in patient reported outcome measures using self-reported symptom severity and interference with daily activities using the MDASI-BT with treatment response and progression-free and overall survival. [ Time Frame: Study Calendar, last collection of QOL Questioner ]Proportion of patients that have an improvement in quality of life
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- INCLUSION CRITERIA:
- Patients must have newly diagnosed histologically confirmed primary glioblastoma or gliosarcoma
- Patients must have undergone a gross total or near gross total resection of unifocal, confined to the supratentorial compartment tumor.
- Patient must have completed chemoradiation (external beam radiation with concurrent temozolomide) a maximum of 5 weeks prior to initiation of study therapy.
- Age greater than or equal to 18 years.
- Karnofsky greater than or equal to 70%
Patients must have adequate organ and marrow function as defined below:
- Absolute neutrophil count greater than or equal to 1,500/mcL
- Platelet Count >100,000/mcL
- Hemoglobin > 9.0 g/dL (may be transfused to achieve this level)
- BUN less than or equal to 30 mg/dL
- Serum creatinine less than or equal to 1.7 mg/dL or creatinine clearance as measured by 24 hour urine collection as > 60 ml/min.
- Total bilirubin (except patients with Gilbert s Syndrome, who are eligible for the study but exempt from the total bilirubin eligibility criterion) less than or equal to 2.0 mg/dL
- ALT and AST less than or equal to 2.5x institutional upper limit of normal.
The effects of study treatment on the developing human fetus are unknown. For this reason, participants of reproductive potential must agree to use adequate contraception which includes a combination of TWO of the following:
- Barrier method of contraception: condoms (male or female) with or without a spermicidal agent, diaphragm, or cervical cap with spermicide
- Hormone-based contraceptive
- Tubal ligation
Note: Consider use in females only or both male and female participants starting from the enrollment and for the duration of study treatment and up to 6 months (women) after the last dose of the study and 6 months (men) after the last dose of the drug temozolomide. Should a woman become pregnant or
suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
-The patient must be able to understand and be willing to sign a written informed consent document.
- Definitive clinical or radiologic evidence of progressive disease.
- Prior placement of Gliadel wafer or local brachytherapy. Note: Tumor Treating Fields are allowed.
- Patients who are receiving any other investigational agents.
- Patients who have a history of receiving immune therapy, such as a vaccine therapy, dendritic cell vaccine or intracavitary or convectional enhanced delivery of therapy.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, ipilimumab or temozolomide.
- History of allergic reactions attributed to gadolinium contrast.
- History of severe hypersensitivity reaction to any monoclonal antibody.
- Prior or concurrent malignancy unless its natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen.
- Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of
immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome or CIDP, myasthenia gravis; systemic autoimmune disease such as SLE, connective tissue diseases, scleroderma, inflammatory bowel disease
(IBD), Crohn s, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome. Such diseases should be excluded because of the risk of recurrence or exacerbation of disease.
Note: Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren s syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.
-The patient must not be currently on a corticosteroid dose greater than physiologic replacement dosing defined as 30 mg of cortisone per day or its equivalent. Patients must have stopped corticosteroids above this threshold at least 7 days prior to initiation of study
-Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations (within timeframes identified in the bullets below) that
would limit compliance with study requirements.
-Pregnant women are excluded from this study because study treatment potential for teratogenic or abortifacient effects is unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to study treatment of the mother,
breastfeeding should be discontinued.
-Known active, chronic or history of hepatitis infection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04817254
|Contact: NCI NOB Referral Group||(866) firstname.lastname@example.org|
|Contact: Mark R Gilbert, M.D.||(240) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937|
|Principal Investigator:||Mark R Gilbert, M.D.||National Cancer Institute (NCI)|
|Responsible Party:||National Cancer Institute (NCI)|
|Other Study ID Numbers:||
|First Posted:||March 26, 2021 Key Record Dates|
|Last Update Posted:||February 1, 2023|
|Last Verified:||January 30, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||.BTRIS: All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@CTA: All collected IPD will be shared with collaborators under the terms of collaborative agreements.|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
|Time Frame:||BTRIS: Clinical data available during the study and indefinitely.@@@@@@All collected IPD will be available after primary analysis have been published.|
|Access Criteria:||BTRIS: Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Quality of Life
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action